Androgen deprivation therapy in prostate cancer may be associated with cardiovascular risk-- Eric Metcalf
Tuesday, February 2, 2010 (Last Updated: 02/03/2010)
TUESDAY, Feb. 2 (HealthDay News) -- The use of androgen deprivation therapy (ADT) to treat prostate cancer may be associated with cardiovascular risk, according to an article published online Feb. 1 in Circulation.
Glenn N. Levine, M.D., of the Baylor College of Medicine in Houston, and colleagues writing on behalf of the American Heart Association, American Cancer Society and the American Urological Association, cite research finding that ADT may increase the risk of cardiovascular disease by increasing body weight, lowering insulin sensitivity, and/or leading to dyslipidemia.
The authors discuss two recent population-based studies associating ADT with a higher incidence of cardiovascular disease, including one that found higher risks of incident coronary heart disease (hazard ratio, 1.16) and myocardial infarction (hazard ratio, 1.11) in men with prostate cancer treated with a gonadotropin-releasing hormone agonist. Though some other studies have also observed a relationship between ADT and cardiovascular risk, others have not.
"Despite the metabolic effects of ADT and the possible increased cardiovascular risk, it is the consensus of the writing group that there is no clear indication for patients for whom ADT is believed to be beneficial to be referred to internists, endocrinologists, or cardiologists for evaluation before initiation of ADT," the authors write. "There is no reason at present to believe that there is a role for specific cardiac testing or coronary intervention in patients with cardiovascular disease before initiation of ADT."
Several members of the writing group reported financial relationships with pharmaceutical companies and foundations.
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.